Optibrium, a leading developer of software and AI solutions for molecular design, today announced it has secured a strategic financing package with Shawbrook, a specialist UK bank that provides finance to established UK businesses on high growth trajectories.
This multi-million-pound deal will enable Optibrium to continue to build its offering to global pharmaceutical and biotech teams, further increasing the speed and efficiency of their drug discovery timelines. The focus will be on improving the core technologies behind the Company’s software portfolio and building technical capabilities to support further global expansion. Areas of development focus will include Optibrium’s generative chemistry, collaborative design and 3D molecular modelling capabilities.
Following continued investment from Kester Capital since February 2021, Optibrium has experienced rapid adoption of its suite of innovative in silico platforms and AI solutions used to successfully navigate the complex challenges of modern drug discovery. Shawbrook structured the Annual Recurring Revenue (ARR) based financing package to provide both immediate capital for current initiatives and committed facilities to support future opportunities.
The market for computer-aided drug discovery (CADD) is a fast-growing sector, driven by the increasing sophistication and capabilities of software tools that can deliver material cost and time savings for drug developers. Independent market research predicts that the global CADD market will reach $13.1 billion by 2034, rising from $4.2 billion in 2024 at a CAGR of 12%.
Founded in 2009, and operating in the UK and US, Optibrium's software platforms combine rigorous scientific research with advanced computational methods. Over 160 global organisations use the Company’s suite of innovative software for compound design, optimisation and data analysis, which enables research teams to make more informed decisions earlier in the discovery process.
